5-Year ULTIMATE OLE Data: Efficacy, Durability, and Early Treatment Impact

This sponsored special report examines the long-term clinical profile of ublituximab in relapsing multiple sclerosis, with a focus on outcomes from the ULTIMATE open-label extension. Through expert perspective, the series explores how sustained efficacy, durability of response, and evolving treatment strategies are shaping the role of B-cell therapies in MS care.

Long-term data often provide the clearest picture of how a therapy performs in clinical practice, particularly in a chronic disease like multiple sclerosis where durability of effect is critical. In this segment, Bruce Cree, MD, PhD, clinical research director at the UCSF Multiple Sclerosis Center, walks through the structure and intent of the ULTIMATE open-label extension and what it reveals after five years of follow-up.

Drawing on detailed efficacy outcomes, Cree discusses trends in annualized relapse rate and disability progression across both continuous treatment and switch populations, as well as the implications of these findings for long-term disease control. The conversation also explores a broader clinical question in MS care — whether early use of high-efficacy therapy may offer advantages over a traditional escalation approach — and how these data contribute to that ongoing debate.